Moody National Bank Trust Division Sells 5,562 Shares of Abbott Laboratories $ABT

Moody National Bank Trust Division lowered its stake in shares of Abbott Laboratories (NYSE:ABT) by 26.7% during the fourth quarter, HoldingsChannel reports. The fund owned 15,278 shares of the healthcare product maker’s stock after selling 5,562 shares during the quarter. Moody National Bank Trust Division’s holdings in Abbott Laboratories were worth $1,914,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the company. Cloud Capital Management LLC acquired a new position in Abbott Laboratories in the third quarter worth about $29,000. Guerra Advisors Inc bought a new position in Abbott Laboratories in the 3rd quarter valued at $31,000. Delos Wealth Advisors LLC acquired a new position in Abbott Laboratories in the second quarter worth $32,000. Bridge Generations Wealth Management LLC bought a new stake in shares of Abbott Laboratories during the third quarter worth $33,000. Finally, Copia Wealth Management bought a new position in shares of Abbott Laboratories in the third quarter valued at about $38,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Insider Buying and Selling at Abbott Laboratories

In related news, SVP Eric Shroff sold 709 shares of the business’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $81,946.22. Following the sale, the senior vice president directly owned 39,164 shares of the company’s stock, valued at approximately $4,526,575.12. The trade was a 1.78% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP John A. Jr. Mccoy sold 585 shares of the stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $67,614.30. Following the transaction, the vice president owned 24,628 shares of the company’s stock, valued at approximately $2,846,504.24. This trade represents a 2.32% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 3,055 shares of company stock valued at $353,097 over the last quarter. 0.46% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the stock. BTIG Research decreased their price objective on shares of Abbott Laboratories from $145.00 to $140.00 and set a “buy” rating on the stock in a report on Tuesday, February 17th. Piper Sandler decreased their price objective on Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating on the stock in a research report on Friday, January 23rd. Sanford C. Bernstein dropped their target price on Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. Weiss Ratings cut Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, January 26th. Finally, Daiwa Securities Group dropped their price objective on Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating for the company in a report on Friday, January 30th. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, Abbott Laboratories presently has an average rating of “Moderate Buy” and a consensus price target of $136.16.

Abbott Laboratories Trading Down 0.7%

NYSE:ABT opened at $104.10 on Wednesday. The firm has a market capitalization of $181.31 billion, a price-to-earnings ratio of 27.98, a PEG ratio of 1.67 and a beta of 0.74. Abbott Laboratories has a 1-year low of $102.41 and a 1-year high of $139.06. The business’s 50-day moving average price is $111.95 and its two-hundred day moving average price is $122.57. The company has a current ratio of 1.58, a quick ratio of 1.18 and a debt-to-equity ratio of 0.19.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, hitting the consensus estimate of $1.50. The business had revenue of $11.46 billion for the quarter, compared to analyst estimates of $11.80 billion. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. Abbott Laboratories’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same quarter last year, the firm earned $1.34 EPS. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, equities analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.4%. Abbott Laboratories’s dividend payout ratio is currently 67.74%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.